Out-of-Frame CBX3::ALK Fusion Drives ALK Activation and Therapy Response
This study reports targeted DNA sequencing results from a single clinical case of metastatic melanoma harboring a novel CBX3::ALK out-of-frame fusion, which exhibited a marked therapeutic response to ALK inhibition. Targeted DNA analysis confirmed the absence of BRAF and RAS mutations and demonstrated a low tumor mutational burden and microsatellite stability. This dataset is designed to be utilized in conjunction with the matching targeted RNA sequencing data, which has been deposited in the Sequence Read Archive (SRA) under accession PRJNA1402121.